This company will turn around and will market this successful medicine well. The forward guidance along with the ousting of the corruption and heinous shorts of the big institutions will loosen its hold on this life saving company. The SEC are delving further into the manipulation of Dendreon's stock, while momentum within this will provide the impetus for the shorts to cover.
Do not be too overly eager for a buyout, for once a prospect slips away, then what?
By their own merit Dendreon will turn things around.